LAVA THERAP. B.V. EO-12 (4PKB F) stock market data APIs

€0.903 0.02(2.3%)
as of February 12, 2025

LAVA THERAP. B.V. EO-12 Financial Data Overview

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Prev. Close 0.841
Open 0.903
High 0.929
Low 0.9202
52 wk Range 0.86-3.66
Market Cap 23 274 K
Shares Outstanding 26 299 K
Revenue 7 398 K
EPS -0.28
Beta 0.48

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get LAVA THERAP. B.V. EO-12 data using free add-ons & libraries


Get LAVA THERAP. B.V. EO-12 Fundamental Data

LAVA THERAP. B.V. EO-12 Fundamental data includes:

  • Net Revenue: 7 398 K
  • EBITDA: -26 883 000
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get LAVA THERAP. B.V. EO-12 Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2021-06-30
  • EPS/Forecast: -0.27
GET THE PACKAGE

Get LAVA THERAP. B.V. EO-12 End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE
Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat